Table of Contents
The newly published Insight Pharma Reports, Biomanufacturing Capacity Strategies: Developing a Flexible, Scalable, and Lean Biomanufacturing System Report, focus on the need for a more reactive and dynamic biomanufacturing approach than is the current industry standard.
Biomanufacturing is common practice in the life sciences industry and has been continually developed and improved for the last two decades. However, as blockbuster drugs reach the end of their patents, treatment is evolving to become more patient-centric and personalized. The mapping of the human genome has allowed for sophisticated and effective new genetic markers and diagnostic methods to be developed, meaning that personalized medicine is becoming a reality. This has a direct impact on manufacturing, with long-term expected production paradigm shifts in the shape of near-patient manufacturing. Moreover, the rise in incidence of viral pandemics has driven a need for quick set-up, disposable, transportable biomanufacturing. This was a contributing factor to Tamiflu being first to market and will very likely be key in the race to stop the Ebola pandemic.
In addition to covering background information on biomanufacturing and capacity approaches, this report will highlight several technologies, methodologies, and business strategies that can be implemented to improve the capacity and flexibility of biomanufacturing.
Included in this Report:
Detailed the history of biomanufacturing development and the direction for the coming decade
Overview of single-use biomanufacturing techniques and trends, outlining the importance of reactive biomanufacturing
Insight into the Ebola vaccine clinical development, as well as the validation process.
Specific capacity-enhancing approaches ranging from technology solutions to business strategy
Examine the overarching industry pressures that are driving capacity needs, the subsequent regulatory compliance, and where the biggest efficiency and productivity savings can be realized.
Explore the scale-up of biomanufacturing processes to serve commercial scale production, which is currently a major limiting factor in the maturity of this field, and how commercialization of certain therapeutics and regenerative medicines is severely limited by the lack of progression here.
Ventures into the realm of lean thinking and continuous manufacturing methodologies and their application in the field of biomanufacturing with a secondary look at the potential of combining modular facilities with disposable biomanufacturing systems and the technical requirements and advances.
Details a considerable amount with regard to technology transfer and the specific issues relating to biomanufacturing, and outlines some solutions and new approaches to knowledge transfer
Takes a wider view of the context, importance, and impact of biomanufacturing and its capacity to provide a solution to several biotechnology industry challenges.
Provides insight into the field of personalized medicine, cell and gene therapies, and commercial-scale manufacturing vs. near-patient production and the predicted paradigm shift.
Tony Hitchcock, Technical Director, Cobra Biologics
Jerold Martin, Sr. V.P. Global Scientific Affairs, Biopharmaceuticals, Pall Corporation
Arnaud Schmutz, General Manager, Sourcin
Nigel Smart, Managing Partner, Smart Consulting Group
Keith Thompson, CEO, Cell Therapy Catapult
Results Biomanufacturing Capacity Strategies Survey
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
Use this report to: - Assess current market dynamics and estimate future demand for sample preparation in genomics, proteomics and epigenomics. - Gain insight into existing products as well as new developments ...
Respondents Show Vivid Interest in Developing Clinical NGS-based Tests for Infectious Disease Testing Applications The primary goal of this research is to analyze the current and future adoption plans ...
Global Non-alcoholic Steatohepatitis Biomarker Market: Overview Non-alcoholic steatohepatitis (NASH) is liver disease which is categorized under the spectrum of non-alcoholic fatty liver disease (NAFLD). ...